Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড13% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s 2024 agreement with Peptron granted only non-exclusive research rights to evaluate SmartDepot—an ultrasonic spray-dried PLGA microsphere platform for one- to six-month peptide release—without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced. Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins, while recent clarifications excluded tirzepatide from the Peptron program and the company has pivoted toward oral obesity candidates. With resolution weeks away and no disclosed commercial progress, traders assign 87.5% probability to “No.”
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা